Safety and Pharmacokinetics of Single Doses of (+)-Calanolide A, a Novel, Naturally Occurring Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy, Human Immunodeficiency Virus-Negative Human Subjects

פריטים דומים

• Unique Anti-Human Immunodeficiency Virus Activities of the Nonnucleoside Reverse Transcriptase Inhibitors Calanolide A, Costatolide, and Dihydrocostatolide
  מאת: Buckheit, Robert W., et al.
  יצא לאור: (1999)
• Pharmacokinetics of Lopinavir-Ritonavir with and without Nonnucleoside Reverse Transcriptase Inhibitors in Ugandan HIV-Infected Adults
  מאת: Kityo, C., et al.
  יצא לאור: (2010)
• Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects
  מאת: Anderson, Matt S., et al.
  יצא לאור: (2008)
• Pharmacokinetic and Safety Evaluation of BILR 355, a Second-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers
  מאת: Huang, Fenglei, et al.
  יצא לאור: (2008)
• Future of nonnucleoside reverse transcriptase inhibitors
  מאת: Sluis-Cremer, Nicolas
  יצא לאור: (2018)